Eric Schmidt, arguably the best and most influential wall street analyst at Cowen & Co, is quite positive on the abstracts and finds the stock significantly undervalued at these levels. He is the axe on the stock and is very measured and experienced in his analysis..
Yes---I have read his analysis of the abstracts and his resulting investment implication. I would agree that Institutions sitting on the sidelines will push this micro cap significantly higher. He notes that sucess in pancreatic cancer and sarcoma could drive sales to $ 1.5 billion+ in the US alone, with THLD likely to receive around 30 per cent of the economics. With a fully diluted enterprise value of around $450mm the stock will continue outperforming throughout the year. I think we can see a mid-teens on the stock this year.